Analyst Group

Analyst Group Comment on Circio's Research Collaboration with Avenue Biosciences

Källa: MFN
Neutral

Sammanfattning

Circio Holding ASA ingår ett forskningssamarbete med Avenue Biosciences för att förbättra långtidsuttrycket av utsöndrade proteiner. Samarbetet kombinerar deras teknologier, men inga finansiella villkor har offentliggjorts. Analyst Group bedömer den kortsiktiga finansiella betydelsen som begränsad.

Analys

Circio Holding ASA har inlett ett forskningssamarbete med Avenue Biosciences, vilket syftar till att förbättra uttrycket av terapeutiska proteiner. Avenue Biosciences bidrar med sin plattform för att identifiera signalpeptidvarianter som förbättrar utsöndringen av proteiner uttryckta av Circios circVec-teknologi. Initial screening utförs av Avenue Biosciences, följt av tester av Circio. Inga finansiella detaljer har presenterats, vilket gör den omedelbara finansiella effekten begränsad. Samarbetet ses som ett komplement till befintliga partnerskap och stärker Circios position.

Insikter

  • • Samarbetet med Avenue Biosciences fokuserar på att förbättra långtidsuttrycket av utsöndrade proteiner.
  • • Inga finansiella villkor har offentliggjorts, vilket indikerar begränsad kortsiktig finansiell påverkan.
  • • Analyst Group ser samarbetet som en bekräftelse på circVecs potential som en mångsidig plattform.

Circio Holding ASA ("Circio" or "the Company") announced, on the 16th of July 2026, a research collaboration with Avenue Biosciences, a transatlantic protein engineering company, to combine their technologies to improve long-term expression of secreted proteins for the treatment of genetic and chronic diseases. Avenue Biosciences will deploy its machine learning-powered platform, which screens thousands of signal peptide variants, to identify sequences that improve secretion of therapeutic proteins expressed by circVec, with initial screening performed by Avenue Biosciences followed by in vitro and in vivo testing by Circio. No financial terms are disclosed.

Circio Holding ASA ("Circio" or "the Company") announced, on the 16th of July 2026, a research collaboration with Avenue Biosciences, a transatlantic protein engineering company, to combine their technologies to improve long-term expression of secreted proteins for the treatment of genetic and chronic diseases. Avenue Biosciences will deploy its machine learning-powered platform, which screens thousands of signal peptide variants, to identify sequences that improve secretion of therapeutic proteins expressed by circVec, with initial screening performed by Avenue Biosciences followed by in vitro and in vivo testing by Circio. No financial terms are disclosed.

In summary, Analyst Group views the Avenue Biosciences collaboration as an important extension of Circio's 2026 partnership activity that adds a payload-focused complement to the Company's delivery-side collaborations. Given the early stage of the collaboration and the absence of disclosed terms, Analyst Group assesses the near-term financial materiality as limited, while noting the collaboration as a further data point supporting circVec's positioning as a broadly applicable expression platform.

Read Analyst Group’s comment here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.Read more about Analyst Group This is a press release from Analyst Group regarding the publication of a comment on Circio Holding. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.